Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response

The widespread use of high‐dose therapy and autologous stem cell transplantation (ASCT) as well as the introduction of novel agents have significantly improved outcomes in multiple myeloma (MM) enabling long‐term survival. We here analyze factors influencing survival in 865 newly diagnosed MM patien...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Giesen, Nicola (VerfasserIn) , Pritsch, Maria (VerfasserIn) , Löpprich, Martin (VerfasserIn) , Mai, Elias K. (VerfasserIn) , Hillengaß, Jens (VerfasserIn) , Goldschmidt, Hartmut (VerfasserIn) , Raab, Marc-Steffen (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2018
In: Cancer medicine
Year: 2018, Jahrgang: 7, Heft: 2, Pages: 307-316
ISSN:2045-7634
DOI:10.1002/cam4.1283
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1002/cam4.1283
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/cam4.1283
Volltext
Verfasserangaben:Nicola Lehners, Natalia Becker, Axel Benner, Maria Pritsch, Martin Löpprich, Elias Karl Mai, Jens Hillengass, Hartmut Goldschmidt & Marc-Steffen Raab

MARC

LEADER 00000caa a2200000 c 4500
001 1577561074
003 DE-627
005 20230426230642.0
007 cr uuu---uuuuu
008 180712s2018 xx |||||o 00| ||eng c
024 7 |a 10.1002/cam4.1283  |2 doi 
035 |a (DE-627)1577561074 
035 |a (DE-576)507561074 
035 |a (DE-599)BSZ507561074 
035 |a (OCoLC)1341013728 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Giesen, Nicola  |d 1983-  |e VerfasserIn  |0 (DE-588)141844272  |0 (DE-627)631828524  |0 (DE-576)32643657X  |4 aut 
245 1 0 |a Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation  |b impact of clinical risk factors and sustained response  |c Nicola Lehners, Natalia Becker, Axel Benner, Maria Pritsch, Martin Löpprich, Elias Karl Mai, Jens Hillengass, Hartmut Goldschmidt & Marc-Steffen Raab 
264 1 |c 2018 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a First published: 28 December 2017 
500 |a Gesehen am 12.07.2018 
520 |a The widespread use of high‐dose therapy and autologous stem cell transplantation (ASCT) as well as the introduction of novel agents have significantly improved outcomes in multiple myeloma (MM) enabling long‐term survival. We here analyze factors influencing survival in 865 newly diagnosed MM patients who underwent first‐line ASCT at our center between 1993 and 2014. Relative survival and conditional survival were assessed to further characterize long‐term survivors. Achievement of complete response (CR) post‐ASCT was associated with prolonged progression‐free survival (PFS) in the whole cohort and with significantly superior overall survival (OS) in the subgroup of patients receiving novel agent‐based induction therapy. Landmark analyses performed at 1, 3, and 5 years post‐ASCT revealed that sustainment of any response had a highly significant influence on survival with no significant differences between sustained CR and sustained inferior responses. Furthermore, outcome was independently improved by administration of maintenance therapy. A subset of patients did experience long‐term survival >15 years. However, conditional survival demonstrated a persistent risk of myeloma‐associated death and cumulative relative survival curves did not show development of a clear plateau, even in prognostically advantageous groups. In conclusion, in this large retrospective study, sustained response after first‐line ASCT was found to be a major prognostic factor for OS independent of depth of sustained response. Administration of maintenance therapy further improved outcome, supporting the hypothesis that interventions to prolong responses achieved post‐ASCT may be essential to reach long‐term survival, especially in the setting of persisting residual disease. 
700 1 |a Pritsch, Maria  |d 1958-  |e VerfasserIn  |0 (DE-588)11816435X  |0 (DE-627)694727121  |0 (DE-576)291747450  |4 aut 
700 1 |a Löpprich, Martin  |d 1985-  |e VerfasserIn  |0 (DE-588)1135283591  |0 (DE-627)890242518  |0 (DE-576)453561241  |4 aut 
700 1 |a Mai, Elias K.  |d 1985-  |e VerfasserIn  |0 (DE-588)1049182545  |0 (DE-627)781300274  |0 (DE-576)403130999  |4 aut 
700 1 |a Hillengaß, Jens  |d 1974-  |e VerfasserIn  |0 (DE-588)124918549  |0 (DE-627)368073823  |0 (DE-576)294568298  |4 aut 
700 1 |a Goldschmidt, Hartmut  |d 1956-  |e VerfasserIn  |0 (DE-588)102258023X  |0 (DE-627)717003809  |0 (DE-576)365637386  |4 aut 
700 1 |a Raab, Marc-Steffen  |d 1973-  |e VerfasserIn  |0 (DE-588)124052460  |0 (DE-627)706520998  |0 (DE-576)293998027  |4 aut 
773 0 8 |i Enthalten in  |t Cancer medicine  |d Hoboken, NJ : Wiley, 2012  |g 7(2018), 2, Seite 307-316  |h Online-Ressource  |w (DE-627)71860153X  |w (DE-600)2659751-2  |w (DE-576)366682164  |x 2045-7634  |7 nnas  |a Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation impact of clinical risk factors and sustained response 
773 1 8 |g volume:7  |g year:2018  |g number:2  |g pages:307-316  |g extent:10  |a Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation impact of clinical risk factors and sustained response 
856 4 0 |u http://dx.doi.org/10.1002/cam4.1283  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1002/cam4.1283  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20180712 
993 |a Article 
994 |a 2018 
998 |g 124052460  |a Raab, Marc-Steffen  |m 124052460:Raab, Marc-Steffen  |d 910000  |d 910100  |e 910000PR124052460  |e 910100PR124052460  |k 0/910000/  |k 1/910000/910100/  |p 9  |y j 
998 |g 102258023X  |a Goldschmidt, Hartmut  |m 102258023X:Goldschmidt, Hartmut  |d 910000  |d 910100  |e 910000PG102258023X  |e 910100PG102258023X  |k 0/910000/  |k 1/910000/910100/  |p 8 
998 |g 124918549  |a Hillengaß, Jens  |m 124918549:Hillengaß, Jens  |d 910000  |d 910100  |e 910000PH124918549  |e 910100PH124918549  |k 0/910000/  |k 1/910000/910100/  |p 7 
998 |g 1049182545  |a Mai, Elias K.  |m 1049182545:Mai, Elias K.  |d 910000  |d 910100  |e 910000PM1049182545  |e 910100PM1049182545  |k 0/910000/  |k 1/910000/910100/  |p 6 
998 |g 1135283591  |a Löpprich, Martin  |m 1135283591:Löpprich, Martin  |p 5 
998 |g 11816435X  |a Pritsch, Maria  |m 11816435X:Pritsch, Maria  |d 910000  |d 910100  |e 910000PP11816435X  |e 910100PP11816435X  |k 0/910000/  |k 1/910000/910100/  |p 4 
998 |g 141844272  |a Giesen, Nicola  |m 141844272:Giesen, Nicola  |d 910000  |d 910100  |e 910000PG141844272  |e 910100PG141844272  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1577561074  |e 3017490505 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation","subtitle":"impact of clinical risk factors and sustained response","title_sort":"Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation"}],"note":["First published: 28 December 2017","Gesehen am 12.07.2018"],"origin":[{"dateIssuedDisp":"2018","dateIssuedKey":"2018"}],"id":{"eki":["1577561074"],"doi":["10.1002/cam4.1283"]},"relHost":[{"language":["eng"],"part":{"text":"7(2018), 2, Seite 307-316","issue":"2","pages":"307-316","year":"2018","extent":"10","volume":"7"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"71860153X","id":{"eki":["71860153X"],"zdb":["2659751-2"],"issn":["2045-7634"]},"title":[{"title_sort":"Cancer medicine","title":"Cancer medicine"}],"pubHistory":["1.2012 -"],"note":["Gesehen am 07.05.13"],"origin":[{"dateIssuedDisp":"2012-","publisher":"Wiley","dateIssuedKey":"2012","publisherPlace":"Hoboken, NJ"}],"disp":"Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation impact of clinical risk factors and sustained responseCancer medicine","type":{"bibl":"periodical","media":"Online-Ressource"}}],"recId":"1577561074","physDesc":[{"extent":"10 S."}],"name":{"displayForm":["Nicola Lehners, Natalia Becker, Axel Benner, Maria Pritsch, Martin Löpprich, Elias Karl Mai, Jens Hillengass, Hartmut Goldschmidt & Marc-Steffen Raab"]},"person":[{"role":"aut","given":"Nicola","family":"Giesen","display":"Giesen, Nicola"},{"family":"Pritsch","display":"Pritsch, Maria","given":"Maria","role":"aut"},{"display":"Löpprich, Martin","family":"Löpprich","role":"aut","given":"Martin"},{"given":"Elias K.","role":"aut","display":"Mai, Elias K.","family":"Mai"},{"role":"aut","given":"Jens","display":"Hillengaß, Jens","family":"Hillengaß"},{"role":"aut","given":"Hartmut","family":"Goldschmidt","display":"Goldschmidt, Hartmut"},{"display":"Raab, Marc-Steffen","family":"Raab","given":"Marc-Steffen","role":"aut"}],"language":["eng"]} 
SRT |a GIESENNICOANALYSISOF2018